Topical treatment of basal cell carcinoma with tazarotene: A clinicopathological study on a large series of cases

British Journal of Dermatology

Volumn 151, Issue 1, 2004, Pages 148-156

  Bianchi, L ^a   Orlandi, A ^a   Campione, E ^a   Angeloni, C ^a   Costanzo, A ^a   Spagnoli, L G ^a   Chimenti, S ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Apoptosis; Basal cell carcinoma; Proliferation; Retinoic acid receptors; Tazarotene; Therapy

Indexed keywords

RETINOIC ACID RECEPTOR; TAZAROTENE;

ADULT; AGED; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CANCER RECURRENCE; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, BASAL CELL; CELL DIVISION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; NICOTINIC ACIDS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, RETINOIC ACID; RETINOL-BINDING PROTEINS; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 4043112728     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06044.x     Document Type: Article

References (42)

1. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 (Suppl. 61): 1-6.
2. Wennberg AM. Basal cell carcinoma - new aspects of diagnosis and treatment. Acta Derm Venereol Suppl (Stockh) 2000; 209; 5-25.
3. Reymann F. Basal cell carcinoma of the skin recurrence rate after different types of treatment: a review. Dermatologica 1980; 161: 217-26.
4. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315-28.
5. Thissen MRTM, Neumann MHA, Schouten LJ. A systemic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-83.
6. Marghoob AA. Basal and squamous cell carcinomas: what every primary care physician should know. Postgrad Med 1997; 102: 139-59.
7. Martinez JC, Otley CC. The management of melanoma and non-melanoma skin cancer: a review for the primary care physician. Mayo Clin Proc 2001; 76: 1253-63.
8. Vine JE. Skin cancer update. Treatment alternatives for basal-cell and squamous-cell carcinoma. N J Med 2001; 98: 35-7.
9. Vander Straten M, Lee P, Weitzul S et al. Advances in the treatment of basal cell carcinoma: the promise of pharmacologic therapy. Adv Dermatol 2000; 16: 299-318.
10. Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer: does it have a future? Cancer 2002; 94: 477-85.
11. Buechner SA, Wernil M, Harr T et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest 1997; 100: 2691-6.
12. Gibbs P, Gonzalez R, Lee LA, Walsh P. Medical management of cutaneous malignancies. Clin Dermatol 2001; 19; 298-304.
13. Urosevic M, Maier T, Benninghoff B et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139: 1325-32.
14. Bastiaens MT, Hoefnagel JJ, Bruijn JA et al. Differences in age, site distributions, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 1998; 110: 880-4.
15. Love JM, Gudas LJ, Vitamin A, differentiation and cancer. Curr Opin Cell Biol 1994; 6: 825-31.
16. Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996; 10: 1031-9.
17. Napgal S, Chandraratna RA. Recent development in receptor-selective retinoids. Curr Pharm Des 2000; 6: 919-31.
18. Chandraratna RA. Future trends: a new generation of retinoids. J Am Acad Dermatol 1998; 39: S149-52.
19. Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 1997; 37: S12-7.
20. Thacher SM, Vasudevan J, Chandraratna RA. Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des 2000; 6: 25-58.
21. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999; 341: 1767-8.
22. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
23. Spagnoli LG, Orlandi A, Santeusanio G. Foam cells of the rabbit atherosclerotic plaque arrested in metaphase by colchicine show a macrophage phenotype. Atherosclerosis 1991; 88: 87-92.
24. Elder D, Elenitsas R, Jaworsky C, Johnson B Jr, eds. Lever's Histopathology of the Skin, 8th edn. Philadelphia: Lippincott-Raven, 1997.
25. Kamradt J, Reichrath J. Expression of retinoic acid receptor proteins in basal cell carcinomas: an immunohistochemical analysis. J Histochem Cytochem 1996; 44: 1415-20.
26. Stockfleth E, Sterry W. New treatment modalities for basal cell carcinoma. Recent Results Cancer Res 2002; 160: 259-68.
27. Widschwendter M, Berger J, Daxenbichler G et al. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 1997; 57: 4158-61.
28. Khuri FR, Lotan R, Kemp BL et al. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 2000; 18: 2798-804.
29. Li Y, Dawson MI, Agadir A et al. Regulation of RAR beta expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: effect on growth inhibition and apoptosis induction. Int J Cancer 1998; 75: 88-95.
30. Sun SY, Wan H, Yue P et al. Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. J Biol Chem 2000; 275: 17149-53.
31. Orlandi A, Bianchi L, Costanzo A et al. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J Invest Dermatol 2004; 122: 1037-41.
32. De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991; 5: 2924-33.
33. Xu XC, Lee JS, Lee JJ et al. Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. J Natl Cancer Inst 1999; 91: 1317-21.
34. Gebert JF, Moghal N, Frangioni JV et al. High frequency of retinoic acid receptor beta abnormalities in human lung cancer. Oncogene 1991; 6: 1859-68.
35. Raffo P, Emionite L, Colucci L et al. Retinoid receptors: pathways of proliferation inhibition and apoptosis induction in breast cancer cell lines. Anticancer Res 2000; 20; 1535-43.
36. Huang DC, Adams JM, Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J 1998; 17: 1029-39.
37. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805.
38. Barrett TL, Smith KJ, Hodge JJ et al. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. J Am Acad Dermatol 1997; 37: 430-7.
39. Campbell C, Quinn AG, Ro YS et al. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol 1993; 100: 746-8.
40. Ong DE, Newcomer ME, Chyntil F. Cellular retinoid-binding proteins. In: The Retinoids: Biology, Chemistry and Medicine (Sporn MB, Roberts AB, Goodman DS. eds). New York: Raven Press, 1994; 283-317.
41. Husmann M, Hoffmann B, Stump DG et al. A retinoic acid response element from the rat CRBP-I promoter is activated by an RAR/RXR heterodimer. Biochem Biophys Res Commun 1992; 187: 1558-64.
42. Boerman MH, Napoli JL. Cellular retinol-binding protein supported retinoic acid synthesis. Relative roles of microsomes and cytosol. J Biol Chem 1996; 271: 5610-6.